AS
n = 84

EnteroSpA
n = 40 (CD: n = 12; UC: n = 28)

Statistical significance

Sex (M/F)

41:43

9:31 (CD: 3:9; UC: 6:22)

0.005

Race (n=nr) M/F
Caucasians
Asians
Africans
Mixed

(n=39); 18:21
(n=35); 17: 18
(n=11); 6:5
0

(n= 18); 3: 15
(n=14); 5: 9
(n=7); 1: 6
(n=1)  0:1

 Age (mean ± SD)

49.6 ± 14.1)

43.4 ± 12.8)

NS

Age at diagnosis (mean ± SD)

37.8 ± 14

45 ± 13.7

NS

Disease duration

11.5 ± 9.7

9.3 ± 12.7

NS

Delay in diagnosis

7.1 ± 6.5

4.1 ± 5.8

0.01

HLA-B27
Positive
Negative
Not done

23/84 (27.3%)
38/84 (45.2%)
23/84 (27.3%)

2/40 (5%)
26/40 (65%)
12/40 (30%)

Enthesitis pain

25/77 (32.5%)

14/35 (40%)

0.02

Associated iritis

24/80 (30%)

12/40 (30%) [CD n=4; UC n=8)

Associated psoriasis

4/80 (5%)

3/40 (7.5%) [CD n=2; UC n=1)

Night pain

6.1 ± 2.8

5.7 ± 3.2

NS

BASDAI score (mean ± SD)

6.2 ± 1.7

5.7 ± 1.9

NS

ESR

16.2 ± 17

21.5 ± 18

NS

CRP

7.4 ± 7.9

10.8 ± 14.5

NS

BASFI score (mean ± SD)

4.8 ± 2.7

4.7 ± 2.9

NS

Wbw

5.6 ± 2.6

5.6 ± 2.7

NS

Wb6m

6.3 ± 2.4

6.2 ± 2.7

NS

Subjects on medication ( yes / from total responders)

66 / 78 (84.6 %)

24/40 (58.5%)

0.005

Pain killers

57 /76 (75%)

21/40 (51.2%)

0.05

NSAIDs

22 /76 (28.9%)

5 /40 (12.2%)

NS*

Steroids

5/73 (6.9%)

5/ 40 (12.2%)

NS

SZP

4/74 (4.7%)

9 /40 (22%)

0.01

MTX

2/72 (2.8%)

2 / 20 (4.9%)

NS

aTNF-α

2/72 (2.8%)

0 /40

NS